1. Home
  2. INBS vs APRE Comparison

INBS vs APRE Comparison

Compare INBS & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intelligent Bio Solutions Inc.

INBS

Intelligent Bio Solutions Inc.

N/A

Current Price

$1.69

Market Cap

6.5M

Sector

Health Care

ML Signal

N/A

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

N/A

Current Price

$0.52

Market Cap

5.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
INBS
APRE
Founded
2016
2006
Country
United States
United States
Employees
N/A
8
Industry
Medical Specialities
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5M
5.7M
IPO Year
2019
2019

Fundamental Metrics

Financial Performance
Metric
INBS
APRE
Price
$1.69
$0.52
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $3.30
AVG Volume (30 Days)
30.9K
★ 271.1K
Earning Date
11-11-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 21.22
EPS
N/A
★ N/A
Revenue
★ $1,980,484.00
N/A
Revenue This Year
$44.72
N/A
Revenue Next Year
$44.26
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$0.41
52 Week High
$24.90
$1.49

Technical Indicators

Market Signals
Indicator
INBS
APRE
Relative Strength Index (RSI) 49.82 39.88
Support Level $1.52 N/A
Resistance Level $1.92 $0.81
Average True Range (ATR) 0.10 0.06
MACD 0.04 -0.01
Stochastic Oscillator 80.95 44.23

Price Performance

Historical Comparison
INBS
APRE

About INBS Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. Its current active product is the Intelligent Fingerprinting Platform, consisting of a proprietary portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader. Its flagship product, the Intelligent Fingerprinting Drug Screening System, is a two-part system of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse, including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The Company operates in APAC, the UK, the Americas, and the rest of the world, with maximum revenue from the United Kingdom.

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Share on Social Networks: